{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:55:19Z","timestamp":1792896919471,"version":"4.5.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,15]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD (cGVHD) remain of high importance. In this prospective, multicenter, phase 2 trial, ruxolitinib, an oral inhibitor of Janus kinase (JAK) 1 and 2, was administered as maintenance therapy after reduced-intensity allogeneic hematopoietic cell transplantation (HCT). GVHD prophylaxis consisted of tacrolimus and methotrexate. Ruxolitinib began between day\u00a0+30 to 100 and was administered continuously in 28-day cycles for up to 24 cycles. Seventy-eight participants were enrolled before HCT; 63 participants received the intervention. The median start date of ruxolitinib after HCT was day\u00a0+45. The most common grade \u22653 adverse events were neutropenia, thrombocytopenia, and anemia. Seven participants experienced grade \u22653 infectious events. GVHD-free, relapse-free survival at 1 year after HCT, the primary end point, was 70%. Grade 3 to 4 acute GVHD at 6\u00a0months was 4.8%, and moderate-severe cGVHD at 2 years was 16%. cGVHD requiring systemic therapy was 9.5% at 1 year and 13% at 2 years. Overall survival and progression-free survival at 2 years were 76% and 68%, respectively. Prolonged administration of ruxolitinib following HCT is associated with low rates of clinically significant cGVHD. The incorporation of JAK inhibition into GVHD prevention approaches warrants further investigation. This trial was registered at www.clinicaltrials.gov as #NCT03286530.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024028005","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T20:05:03Z","timestamp":1742414703000},"page":"2312-2316","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"first","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"2Department of Data Science, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura W.","family":"Knight","sequence":"additional","affiliation":[{"name":"3Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"3Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-6728","authenticated-orcid":false,"given":"Shilton E.","family":"Dhaver","sequence":"additional","affiliation":[{"name":"3Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"White","sequence":"additional","affiliation":[{"name":"3Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"4Department of Hematology-Oncology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-8990","authenticated-orcid":false,"given":"Mark A.","family":"Schroeder","sequence":"additional","affiliation":[{"name":"5Bone Marrow Transplantation and Leukemia Section, Division of Oncology, Washington University School of Medicine in Saint Louis, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-4766","authenticated-orcid":false,"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooho","family":"Chung","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"McAfee","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-6961","authenticated-orcid":false,"given":"Richard A.","family":"Newcomb","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Spitzer","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"1Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[{"name":"8Center for Leukemia, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2025051511212700500_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"issue":"18","key":"2025051511212700500_bib2","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025051511212700500_bib3","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"25","key":"2025051511212700500_bib4","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025051511212700500_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10\/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"issue":"5","key":"2025051511212700500_bib6","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41375-024-02225-7","article-title":"ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"2025051511212700500_bib7","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2025051511212700500_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025051511212700500_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025051511212700500_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41409-024-02266-7","article-title":"Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell\u00a0transplantation in aplastic anemia patients","volume":"59","author":"Zhang","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"suppl 1","key":"2025051511212700500_bib11","first-page":"20","article-title":"Randomized multicenter trial of calcineurin-free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in unrelated and haploidentical transplantations: a final analysis of the primary endpoint","volume":"59","author":"Moiseev","year":"2024","journal-title":"Bone\u00a0Marrow Transpl"},{"issue":"8","key":"2025051511212700500_bib12","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2025051511212700500_bib13","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025051511212700500_bib14","first-page":"JCO2400184","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","author":"Shaffer","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025051511212700500_bib15","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.bbmt.2020.08.015","article-title":"Peritransplantation use of ruxolitinib in myelofibrosis","volume":"26","author":"Ibrahim","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2025051511212700500_bib16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2025051511212700500_bib17","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025051511212700500_bib18","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","article-title":"Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial","volume":"30","author":"Chen","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025051511212700500_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2023-180142","article-title":"Effective\u00a0prevention of steroid-requiring chronic graft-vs.-host disease with B cell depletion: a randomized, placebo-controlled\u00a0trial [abstract]","volume":"142","author":"Cutler","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025051511212700500_bib20","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood-2023-178645","article-title":"Updated findings of a phase II study of ruxolitinib pre-during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis [abstract]","volume":"142","author":"Hobbs","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025051511212700500_bib21","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bbmt.2018.01.002","article-title":"Blood and Marrow Transplant Clinical Trials Network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials","volume":"24","author":"Pasquini","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2025051511212700500_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3324\/haematol.2016.144139","article-title":"Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide","volume":"102","author":"McCurdy","year":"2017","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/20\/2312\/2374678\/blood_bld-2024-028005-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/20\/2312\/2374678\/blood_bld-2024-028005-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:21:34Z","timestamp":1747322494000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/20\/2312\/536227\/Low-rates-of-chronic-graft-versus-host-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":22,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028005","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}